Bellicum pharmaceuticals to present at the biocentury 23rd annual newsmakers in the biotech industry conference

Houston--(business wire)--bellicum pharmaceuticals, inc. (nasdaq:blcm), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that tom farrell, president and ceo, will present at the biocentury 23rd annual newsmakers in the biotech industry conference. the presentation will take place on friday, september 9, 2016 at 9:30 a.m. edt in new york city. a live webcast of the presentation may be accessed from the news & events section of the bellicum website. an archived version of the webcast will be available for replay for at least two weeks following the event. about bellicum pharmaceuticals bellicum is a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. bellicum is using its proprietary chemical induction of dimerization (cid) technology platform to engineer and control components of the immune system. bellicum is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (hsct), and car t and tcr cell therapies. more information can be found at www.bellicum.com.
BLCM Ratings Summary
BLCM Quant Ranking